Reports Q4 revenue $79.545M, consensus $75.64M. "It has been exciting to build on our strong initial launch by doubling ORLADEYO revenues in our second year, and to see the expanding global reach of an oral, once-daily therapy that is changing the lives of patients with HAE and their families," said Jon Stonehouse, president and chief executive officer of BioCryst.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BCRX:
- BioCryst to Present at Upcoming Investor Conferences
- BioCryst Dives after Mixed Earnings
- BioCryst Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Key Milestones
- BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
- BioCryst reports inducement grants under Nasdaq listing rule
